Jennifer L. Caswell-Jin

Featured in: Favicon

nature.com Favicon

jamanetwork.com Favicon

annualreviews.org Favicon

ascopubs.org Favicon

Articles

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology

May 20, 2024 | ascopubs.org | Rachel A. Freedman |Jennifer L. Caswell-Jin |Mark R. Somerfield

1 This is a rapid recommendation update of that guideline that addresses, in turn, the adjuvant use of the cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →